magrolimab: Clinical Trials

20 trials of magrolimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 7 terminated, 4 withdrawn, 2 active not recruiting. 20 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 120Completed 7, Terminated 7, Withdrawn 4, Active not recruiting 2
Phase 26Terminated 4, Completed 1, Withdrawn 1

Follow magrolimab: new trials by email Literature Review of magrolimab trials Research Report on magrolimab

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Sabatolimab, Magrolimab, Azacitidine - Myelodysplastic Syndromes, Acute Myeloid Leukemia
Phase 1 / Phase 2WithdrawnNovartis Pharmaceuticals2024-12-202024-04-11
Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase 1WithdrawnCity of Hope Medical Center2024-10-092024-09-19
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma
Phase 1WithdrawnNational Cancer Institute (NCI)2024-03-052024-05-02
Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma
Magrolimab, Cisplatin, Gemcitabine - Advanced Urothelial Carcinoma
Phase 1WithdrawnInsel Gruppe AG, University Hospital Bern2023-06-212024-07-05
Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors
Magrolimab - Brain Cancer, Malignant Brain Tumor
Phase 1CompletedUniversity of California, San Francisco132022-04-222025-07-09
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Obinutuzumab, Venetoclax, Magrolimab - Follicular Lymphoma, Marginal Zone Lymphoma
Phase 1CompletedNational Cancer Institute (NCI)112021-12-162025-02-04
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
ONO-7913, ONO-4538, Fluorouracil - Unresectable Colorectal Cancer
Phase 1Active not recruitingOno Pharmaceutical Co., Ltd.652021-09-232026-10-07
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - High Risk Neuroblastoma, Recurrent Neuroblastoma
Phase 1TerminatedNational Cancer Institute (NCI)122021-08-312026-06-30
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
ONO-7913, ONO-4538, Oxaliplatin - Metastatic Pancreatic Cancer
Phase 1Active not recruitingOno Pharmaceutical Co., Ltd.322021-07-302026-10-07
Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
Biospecimen Collection, Computed Tomography, Magrolimab - Mycosis Fungoides, Recurrent Mycosis Fungoides
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)82021-04-062025-10-16
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Azacitidine, Magrolimab, Venetoclax - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center1102020-07-282026-04-23
A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
Atezolizumab, Hu5F9-G4 - Acute Myeloid Leukemia
Phase 1TerminatedHoffmann-La Roche132019-10-082022-02-21
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
Atezolizumab, Enfortumab Vedotin, Niraparib - Urothelial Carcinoma, Bladder Cancer
Phase 1 / Phase 2TerminatedHoffmann-La Roche2722019-06-012026-08-03
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
AZD9150, Acalabrutinib, AZD6738 - NHL, DLBCL
Phase 1CompletedAcerta Pharma BV302018-06-192022-08-15
Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy
Magrolimab, Avelumab - Ovarian Cancer
Phase 1CompletedGilead Sciences342018-05-232024-04-01
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
Magrolimab, Azacitidine - Hematological Malignancies
Phase 1TerminatedGilead Sciences2582017-09-082025-01-17
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Magrolimab, Rituximab, Gemcitabine - Non Hodgkin Lymphoma
Phase 1 / Phase 2TerminatedGilead Sciences1782016-11-212025-05-29
Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer
Magrolimab, Cetuximab - Solid Tumor, Colorectal Cancer
Phase 1 / Phase 2CompletedGilead Sciences782016-11-022021-03-01
CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies
Hu5F9-G4 - Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase 1CompletedGilead Sciences202015-11-012019-02-21
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
Hu5F9-G4 - Solid Tumor
Phase 1CompletedGilead Sciences882014-08-012019-02-05

Conditions studied

Leukemia, Myeloid, Acute (5)  ·  Myelodysplastic Syndromes (3)  ·  Lymphoma, Non-Hodgkin (2)  ·  Brain Neoplasms (1)  ·  Carcinoma, Transitional Cell (1)  ·  Colorectal Neoplasms (1)  ·  Hematologic Neoplasms (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)  ·  Lymphoma, Follicular (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Mycosis Fungoides (1)  ·  Neuroblastoma (1)  ·  Osteosarcoma (1)

Sponsors

Gilead Sciences (6)  ·  National Cancer Institute (NCI) (4)  ·  Hoffmann-La Roche (2)  ·  Ono Pharmaceutical Co., Ltd. (2)  ·  Acerta Pharma BV (1)  ·  City of Hope Medical Center (1)  ·  Insel Gruppe AG, University Hospital Bern (1)  ·  M.D. Anderson Cancer Center (1)  ·  Novartis Pharmaceuticals (1)  ·  University of California, San Francisco (1)

Countries

United States (14)  ·  United Kingdom (5)  ·  Japan (2)  ·  Australia (1)  ·  Canada (1)  ·  France (1)  ·  Greece (1)  ·  South Korea (1)  ·  Spain (1)  ·  Taiwan (1)

Top investigators

Project Leader (2)  ·  Bernhard Kiss, Professor (1)  ·  Chris Takimoto, MD (1)  ·  Haider S Mahdi (1)  ·  Howard Colman, MD PhD FAAN (1)  ·  Ian Flinn, MD, PhD (1)  ·  Mark Chao, MD PhD (1)  ·  Mark J Roschewski, M.D. (1)  ·  Michael S Khodadoust (1)  ·  Monzr M Al Malki, MD (1)  ·  Naval G Daver (1)  ·  Nicholas Whipple, MD, MPH (1)

Results publications

PMID 26390038, PMID 30811285, PMID 31183877, PMID 36888930, PMID 37651261, PMID 39213421, PMID 39293083, PMID 40318595

NIH funding

2017 (2), 2015 (1), 2016 (1), 2023 (1), P30CA015704 (1), P30CA033572 (1), U01CA154967 (1), UM1CA186690 (1), UM1CA186717 (1), UM1CA228823 (1)